Moderna shares double as cancer vaccine data rekindles investor hopes - Reuters
Moderna shares double as cancer vaccine data rekindles investor hopes Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOdGJPaGVZV1B5YXpJY1ZQM3h6X1ZtZmZMQ1k5NTZGX2NUSkdFZU80bHVXY3Z0Uk1kV2xWckJoc3VaTTB2MTd4dnhwaVp4SHk1U0RYMzBRQUtYRW45SFJKQ1hRN3pZd0pIblo1ZGN6aV9KVHZwYkNVUmpKNWhxdlRDTW9wTEtXWUxVdUZuMUJKUHJMeVpIZ1djS3kxeWhnbmNmSzJZUWVGYkwtNm5qWml4TUhzenpyUmlIRjNqa3czTmVORXQyTEY0eHdfdlpiQmFyNXdUcW5rbjJ0MjIwcmc?oc=5" target="_blank">Moderna shares double as cancer vaccine data rekindles investor hopes</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Moderna to replace Warner Bros Discovery on Nasdaq 100 - Reuters
Moderna to replace Warner Bros Discovery on Nasdaq 100 Reuters
October 2, 2026 at 12:12 AMAstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination - Reuters
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination Reuters
October 2, 2026 at 06:58 AMAstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - Reuters
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up Reuters
September 28, 2026 at 10:15 PMUniQure plunges as Huntington's trial data disappoints investors - reuters.com
UniQure plunges as Huntington's trial data disappoints investors reuters.com
September 29, 2026 at 10:11 PMMerck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
September 28, 2026 at 04:14 PMNovartis strikes up to $7.8 billion mRNA deal with China's Abogen - Reuters
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen Reuters
October 2, 2026 at 10:57 AM